A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma

• Main Authors: Guangwei Xu (Author), Tianqi Wang (Author), Yongtao Li (Author), Zhi Huang (Author), Xin Wang (Author), Jianyu Zheng (Author), Shengyong Yang (Author), Yan Fan (Author), Rong Xiang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Indoleamine 2,3-dioxygenase 1 (IDO1) activity links to immune escape of cancers. Inhibition of IDO1 provides a new approach for cancer treatment. Most clinical IDO1 drugs show marginal efficacy as single agents. On basis of molecular docking and pharmacophore modelling, a novel inhibitor Roxyl-WL wa...